Department of Medical Imaging and Interventional Radiology, Cancer Center and State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, China.
Cancer. 2010 Aug 15;116(16):3934-42. doi: 10.1002/cncr.25192.
High-intensity focused ultrasound (HIFU) is a new, noninvasive technique with potential to ablate and inactivate tumors. Treatment of solid tumors with HIFU has been reported. In this study, the safety and effects of HIFU in the clinical therapy of malignant bone tumors were assessed.
Biochemical markers and magnetic resonance imaging (MRI) or positron emission tomography (PET)-computed tomography (CT) were used to evaluate 25 patients with malignant bone tumors before and after HIFU treatment.
HIFU resulted in significant improvement in biochemical markers, and no severe complications were observed. After HIFU treatment, 21 (87.5%) patients were completely relieved of pain, and 24 (100%) experienced significant relief. On the basis of MRI or PET-CT, HIFU was effective: For patients with primary bone tumors, 6 (46.2%) had a complete response, 5 (38.4%) had a partial response, 1 (7.8%) had a moderate response, and 1 suffered progressive disease; the response rate was 84.6%. For patients with metastatic bone tumors, 5 (41.7%) had complete response, 4 (33.3%) had partial response, 1 (8.3%) had a moderate response, 1 (8.3%) had stable disease, and 1 suffered progressive disease; the response rate was 75.0%. The 1-, 2-, 3-, and 5-year survival rates were 100.0%, 84.6%, 69.2%, and 38.5%, respectively, for patients with primary bone tumors and 83.3%, 16.7%, 0%, and 0%, respectively, for patients with metastatic bone tumors. The survival rates for patients with primary bone tumors were significantly better than for those with metastatic tumors.
HIFU safely and noninvasively ablated malignant bone tumors and relieved pain. HIFU ablation should be further investigated, as it appears to be successful in the treatment of primary malignant bone tumors.
高强度聚焦超声（HIFU）是一种新的非侵入性技术，具有消融和灭活肿瘤的潜力。已经有报道使用 HIFU 治疗实体肿瘤。在本研究中，评估了 HIFU 在恶性骨肿瘤临床治疗中的安全性和效果。
使用生化标志物和磁共振成像（MRI）或正电子发射断层扫描（PET）-计算机断层扫描（CT）评估 25 例恶性骨肿瘤患者 HIFU 治疗前后的情况。
HIFU 导致生化标志物显著改善，且未观察到严重并发症。HIFU 治疗后，21 例（87.5%）患者完全缓解疼痛，24 例（100%）患者疼痛明显缓解。根据 MRI 或 PET-CT，HIFU 有效：对于原发性骨肿瘤患者，6 例（46.2%）完全缓解，5 例（38.4%）部分缓解，1 例（7.8%）中度缓解，1 例（8.3%）疾病进展；总缓解率为 84.6%。对于转移性骨肿瘤患者，5 例（41.7%）完全缓解，4 例（33.3%）部分缓解，1 例（8.3%）中度缓解，1 例（8.3%）疾病稳定，1 例（8.3%）疾病进展；总缓解率为 75.0%。原发性骨肿瘤患者的 1 年、2 年、3 年和 5 年生存率分别为 100.0%、84.6%、69.2%和 38.5%，转移性骨肿瘤患者分别为 83.3%、16.7%、0%和 0%。原发性骨肿瘤患者的生存率明显优于转移性骨肿瘤患者。
HIFU 安全、无创地消融恶性骨肿瘤并缓解疼痛。HIFU 消融应进一步研究，因为它似乎在原发性恶性骨肿瘤的治疗中取得了成功。
